Based on the Assembly Biosciences Inc stock forecast from 1 analysts, the average analyst target price for Assembly Biosciences Inc is USD 35.00 over the next 12 months. Assembly Biosciences Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Assembly Biosciences Inc is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Assembly Biosciences Inc’s stock price was USD 16.60. Assembly Biosciences Inc’s stock price has changed by -5.63% over the past week, +2.09% over the past month and +9,190.35% over the last year.
No recent analyst target price found for Assembly Biosciences Inc
No recent average analyst rating found for Assembly Biosciences Inc
Company Overview Assembly Biosciences Inc
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California. Address: Two Tower Place, South San Francisco, CA, United States, 94080 Read Less
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital her...Read More
Frequently Asked Questions About Assembly Biosciences Inc (ASMB) Stock
Based on ratings from 1 analysts Assembly Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ASMB's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ASMB is USD 35.00 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 35.
Unfortunately we do not have enough data on ASMB's stock to indicate if its overvalued.
The last closing price of ASMB's stock was USD 16.60.
The most recent market capitalization for ASMB is USD 0.11B.
Based on targets from 1 analysts, the average taret price for ASMB is projected at USD 35.00 over the next 12 months.
This means that ASMB's stock price may go up by +110.84% over the next 12 months.
We can't find any ETFs which contains Assembly Biosciences Inc's stock.
As per our most recent records Assembly Biosciences Inc has 65 Employees.
Assembly Biosciences Inc's registered address is Two Tower Place, South San Francisco, CA, United States, 94080.
You can get more information about it from Assembly Biosciences Inc's website at https://www.assemblybio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Assembly Biosciences Inc (ASMB) Stock
Based on ratings from 1 analysts Assembly Biosciences Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ASMB's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ASMB is USD 35.00 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 35.
Unfortunately we do not have enough data on ASMB's stock to indicate if its overvalued.
The last closing price of ASMB's stock was USD 16.60.
The most recent market capitalization for ASMB is USD 0.11B.
Based on targets from 1 analysts, the average taret price for ASMB is projected at USD 35.00 over the next 12 months.
This means that ASMB's stock price may go up by +110.84% over the next 12 months.
We can't find any ETFs which contains Assembly Biosciences Inc's stock.
As per our most recent records Assembly Biosciences Inc has 65 Employees.
Assembly Biosciences Inc's registered address is Two Tower Place, South San Francisco, CA, United States, 94080.
You can get more information about it from Assembly Biosciences Inc's website at https://www.assemblybio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ASMB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
